Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif & Nima Rezaei. (2021) Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. Expert Opinion on Biological Therapy 21:12, pages 1575-1590.
Read now
Read now
Parmida Sadat Pezeshki & Nima Rezaei. (2021) Immune checkpoint inhibition in COVID-19: risks and benefits. Expert Opinion on Biological Therapy 21:9, pages 1173-1179.
Read now
Read now
Articles from other publishers (3)
Juanfeng Lao, Can Cao, Xiaoli Niu, Simei Deng, Siqi Ming, Siping Liang, Yuqi Shang, Yulin Yuan, Xiaomin Shi, Zibin Liang, Minhao Wu & Yongjian Wu. (2022) OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer. International Immunopharmacology 108, pages 108813.
Crossref
Crossref
Maofen Jiang, Chunjiao Liu, Dongxiao Ding, Hui Tian & Chaoqun Yu. (2022) Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies. Frontiers in Oncology 12.
Crossref
Crossref
Yimin Xu, Gangcai Zhu, Christopher A. Maroun, Irene X. Y. Wu, Donghai Huang, Tanguy Y. Seiwert, Yong Liu, Rajarsi Mandal & Xin Zhang. (2021) Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. Frontiers in Immunology 12.
Crossref
Crossref